vg_future
8 minutes ago
From the PR, I took this as the second one other than JPAD that was discussed here and ST,
Strengthening the submission is the 265 week (~5-year) Phase 2a trial investigating blarcamesine in mild-to-moderate Alzheimer’s disease, with interim preliminary data published in the peer-rev